secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2022-07-20T23:59:59+00:00
Accession:  0001564590-22-026043
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Bio halts vebicorvir, cuts workforce 30%, CFO exits, extends cash to H1 2024
--------------------------------------------------------------------------------

- Discontinues vebicorvir (VBR) based on interim combo study data showing no benefit in viral parameters.
- Advancing next-gen core inhibitors ABI-H3733 (Phase 1b data H2 2022) and ABI-4334 (Phase 1a starts H2 2022).
- Workforce reduced ~30% (~70 FTEs); CFO Michael Samar departs Aug 12; COO Jason Okazaki becomes President & COO.
- Restructuring costs ~$1.6M; cash runway extended into first half of 2024.
- Prioritizes research: HBV/HDV entry inhibitor, IFNAR agonist, two new viral targets (Q3 2022).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000156459022026043/0001564590-22-026043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000156459022026043/asmb-8k_20220719.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-026043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer